

Recombinant Glycosylated Proteins-United States Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/R833317E7FAMEN.html>

Date: March 2018

Pages: 157

Price: US\$ 3,480.00 (Single User License)

ID: R833317E7FAMEN

Abstracts

Report Summary

Recombinant Glycosylated Proteins-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Recombinant Glycosylated Proteins industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole United States and Regional Market Size of Recombinant Glycosylated Proteins 2013-2017, and development forecast 2018-2023

Main market players of Recombinant Glycosylated Proteins in United States, with company and product introduction, position in the Recombinant Glycosylated Proteins market

Market status and development trend of Recombinant Glycosylated Proteins by types and applications

Cost and profit status of Recombinant Glycosylated Proteins, and marketing status

Market growth drivers and challenges

The report segments the United States Recombinant Glycosylated Proteins market as:

United States Recombinant Glycosylated Proteins Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

New England

The Middle Atlantic

The Midwest

The West

The South

Southwest

United States Recombinant Glycosylated Proteins Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Erythropoietin (EPO)

Monoclonal antibodies (mabs)

Follitropin

United States Recombinant Glycosylated Proteins Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Oncology

Blood Disorders

Auto-immune Diseases

Infectious disease

Growth Hormone Deficiency

United States Recombinant Glycosylated Proteins Market: Players Segment Analysis (Company and Product introduction, Recombinant Glycosylated Proteins Sales Volume, Revenue, Price and Gross Margin):

Hospira

Sandoz International

Teva

Roche

Amgen

Biocon

Dr. Reddy's Laboratories

Celltrion

Mylan

Actavis

Merck

Taj Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and

individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF RECOMBINANT GLYCOSYLATED PROTEINS

- 1.1 Definition of Recombinant Glycosylated Proteins in This Report
- 1.2 Commercial Types of Recombinant Glycosylated Proteins
 - 1.2.1 Erythropoietin (EPO)
 - 1.2.2 Monoclonal antibodies (mabs)
 - 1.2.3 Follitropin
- 1.3 Downstream Application of Recombinant Glycosylated Proteins
 - 1.3.1 Oncology
 - 1.3.2 Blood Disorders
 - 1.3.3 Auto-immune Diseases
 - 1.3.4 Infectious disease
 - 1.3.5 Growth Hormone Deficiency
- 1.4 Development History of Recombinant Glycosylated Proteins
- 1.5 Market Status and Trend of Recombinant Glycosylated Proteins 2013-2023
 - 1.5.1 United States Recombinant Glycosylated Proteins Market Status and Trend 2013-2023
 - 1.5.2 Regional Recombinant Glycosylated Proteins Market Status and Trend 2013-2023

CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Recombinant Glycosylated Proteins in United States 2013-2017
- 2.2 Consumption Market of Recombinant Glycosylated Proteins in United States by Regions
 - 2.2.1 Consumption Volume of Recombinant Glycosylated Proteins in United States by Regions
 - 2.2.2 Revenue of Recombinant Glycosylated Proteins in United States by Regions
- 2.3 Market Analysis of Recombinant Glycosylated Proteins in United States by Regions
 - 2.3.1 Market Analysis of Recombinant Glycosylated Proteins in New England 2013-2017
 - 2.3.2 Market Analysis of Recombinant Glycosylated Proteins in The Middle Atlantic 2013-2017
 - 2.3.3 Market Analysis of Recombinant Glycosylated Proteins in The Midwest 2013-2017
 - 2.3.4 Market Analysis of Recombinant Glycosylated Proteins in The West 2013-2017
 - 2.3.5 Market Analysis of Recombinant Glycosylated Proteins in The South 2013-2017

- 2.3.6 Market Analysis of Recombinant Glycosylated Proteins in Southwest 2013-2017
- 2.4 Market Development Forecast of Recombinant Glycosylated Proteins in United States 2018-2023
 - 2.4.1 Market Development Forecast of Recombinant Glycosylated Proteins in United States 2018-2023
 - 2.4.2 Market Development Forecast of Recombinant Glycosylated Proteins by Regions 2018-2023

CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole United States Market Status by Types
 - 3.1.1 Consumption Volume of Recombinant Glycosylated Proteins in United States by Types
 - 3.1.2 Revenue of Recombinant Glycosylated Proteins in United States by Types
- 3.2 United States Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in New England
 - 3.2.2 Market Status by Types in The Middle Atlantic
 - 3.2.3 Market Status by Types in The Midwest
 - 3.2.4 Market Status by Types in The West
 - 3.2.5 Market Status by Types in The South
 - 3.2.6 Market Status by Types in Southwest
- 3.3 Market Forecast of Recombinant Glycosylated Proteins in United States by Types

CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Recombinant Glycosylated Proteins in United States by Downstream Industry
- 4.2 Demand Volume of Recombinant Glycosylated Proteins by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Recombinant Glycosylated Proteins by Downstream Industry in New England
 - 4.2.2 Demand Volume of Recombinant Glycosylated Proteins by Downstream Industry in The Middle Atlantic
 - 4.2.3 Demand Volume of Recombinant Glycosylated Proteins by Downstream Industry in The Midwest
 - 4.2.4 Demand Volume of Recombinant Glycosylated Proteins by Downstream Industry in The West
 - 4.2.5 Demand Volume of Recombinant Glycosylated Proteins by Downstream Industry

in The South

4.2.6 Demand Volume of Recombinant Glycosylated Proteins by Downstream Industry
in Southwest

4.3 Market Forecast of Recombinant Glycosylated Proteins in United States by
Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF RECOMBINANT GLYCOSYLATED PROTEINS

5.1 United States Economy Situation and Trend Overview

5.2 Recombinant Glycosylated Proteins Downstream Industry Situation and Trend
Overview

CHAPTER 6 RECOMBINANT GLYCOSYLATED PROTEINS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES

6.1 Sales Volume of Recombinant Glycosylated Proteins in United States by Major
Players

6.2 Revenue of Recombinant Glycosylated Proteins in United States by Major Players

6.3 Basic Information of Recombinant Glycosylated Proteins by Major Players

6.3.1 Headquarters Location and Established Time of Recombinant Glycosylated
Proteins Major Players

6.3.2 Employees and Revenue Level of Recombinant Glycosylated Proteins Major
Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 RECOMBINANT GLYCOSYLATED PROTEINS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Hospira

7.1.1 Company profile

7.1.2 Representative Recombinant Glycosylated Proteins Product

7.1.3 Recombinant Glycosylated Proteins Sales, Revenue, Price and Gross Margin of
Hospira

7.2 Sandoz International

7.2.1 Company profile

- 7.2.2 Representative Recombinant Glycosylated Proteins Product
- 7.2.3 Recombinant Glycosylated Proteins Sales, Revenue, Price and Gross Margin of Sandoz International
- 7.3 Teva
 - 7.3.1 Company profile
 - 7.3.2 Representative Recombinant Glycosylated Proteins Product
 - 7.3.3 Recombinant Glycosylated Proteins Sales, Revenue, Price and Gross Margin of Teva
- 7.4 Roche
 - 7.4.1 Company profile
 - 7.4.2 Representative Recombinant Glycosylated Proteins Product
 - 7.4.3 Recombinant Glycosylated Proteins Sales, Revenue, Price and Gross Margin of Roche
- 7.5 Amgen
 - 7.5.1 Company profile
 - 7.5.2 Representative Recombinant Glycosylated Proteins Product
 - 7.5.3 Recombinant Glycosylated Proteins Sales, Revenue, Price and Gross Margin of Amgen
- 7.6 Biocon
 - 7.6.1 Company profile
 - 7.6.2 Representative Recombinant Glycosylated Proteins Product
 - 7.6.3 Recombinant Glycosylated Proteins Sales, Revenue, Price and Gross Margin of Biocon
- 7.7 Dr. Reddy's Laboratories
 - 7.7.1 Company profile
 - 7.7.2 Representative Recombinant Glycosylated Proteins Product
 - 7.7.3 Recombinant Glycosylated Proteins Sales, Revenue, Price and Gross Margin of Dr. Reddy's Laboratories
- 7.8 Celltrion
 - 7.8.1 Company profile
 - 7.8.2 Representative Recombinant Glycosylated Proteins Product
 - 7.8.3 Recombinant Glycosylated Proteins Sales, Revenue, Price and Gross Margin of Celltrion
- 7.9 Mylan
 - 7.9.1 Company profile
 - 7.9.2 Representative Recombinant Glycosylated Proteins Product
 - 7.9.3 Recombinant Glycosylated Proteins Sales, Revenue, Price and Gross Margin of Mylan
- 7.10 Actavis

- 7.10.1 Company profile
- 7.10.2 Representative Recombinant Glycosylated Proteins Product
- 7.10.3 Recombinant Glycosylated Proteins Sales, Revenue, Price and Gross Margin of Actavis
- 7.11 Merck
 - 7.11.1 Company profile
 - 7.11.2 Representative Recombinant Glycosylated Proteins Product
 - 7.11.3 Recombinant Glycosylated Proteins Sales, Revenue, Price and Gross Margin of Merck
- 7.12 Taj Pharmaceuticals
 - 7.12.1 Company profile
 - 7.12.2 Representative Recombinant Glycosylated Proteins Product
 - 7.12.3 Recombinant Glycosylated Proteins Sales, Revenue, Price and Gross Margin of Taj Pharmaceuticals

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF RECOMBINANT GLYCOSYLATED PROTEINS

- 8.1 Industry Chain of Recombinant Glycosylated Proteins
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF RECOMBINANT GLYCOSYLATED PROTEINS

- 9.1 Cost Structure Analysis of Recombinant Glycosylated Proteins
- 9.2 Raw Materials Cost Analysis of Recombinant Glycosylated Proteins
- 9.3 Labor Cost Analysis of Recombinant Glycosylated Proteins
- 9.4 Manufacturing Expenses Analysis of Recombinant Glycosylated Proteins

CHAPTER 10 MARKETING STATUS ANALYSIS OF RECOMBINANT GLYCOSYLATED PROTEINS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy

- 10.2.2 Brand Strategy
- 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Recombinant Glycosylated Proteins-United States Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/R833317E7FAMEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R833317E7FAMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

